



Response under 37 CFR 1.116
Expedited Procedure
Examining Group 1632

FEI 1700
aDoc
7/2/03

Attorney Docket No. 5951.010-US

PATENT

TECH CENTER 1600/2900

FEB 10 2003

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Harris *et al.*

Serial No.: 09/615,571

Group Art Unit: 1632

Filed: July 13, 2000

Examiner: S.D. Priebe

For: Polypeptides Having Phospholipase B Activity And Nucleic Acids Encoding Same

AMENDMENT

Commissioner for Patents
Washington, DC 20231

Sir:

In response to the Office Action dated August 28, 2002, reconsideration of the application in view of the following remarks is requested. It is respectfully submitted that the present amendment presents no new issues or new matter and places this case in condition for allowance. Claims 100-128 are pending in the present application.

I. The Rejection of Claims 100-104, 108-111, 113-115, and 120-124 under 35 U.S.C. § 112, First Paragraph

Claims 100-104, 108-111, 113-115, and 120-124 stand rejected under 35 U.S.C. § 112, first paragraph, "as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention." This rejection is respectfully traversed.

The instant invention is directed to isolated nucleic acid sequences encoding a polypeptide having phospholipase B activity, selected from the group consisting of: (a) a nucleic acid sequence encoding a polypeptide having an amino acid sequence which has at least 80% identity with amino acids 20 to 464 of SEQ ID NO: 2; (b) a nucleic acid sequence having at least 80% homology with

OK to
enter
SDP
7/11/03